Skip to main content

FDA Approvals

Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma

Loretta Fala

Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

Loretta Fala

FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

Cholangiocarcinoma, FDA Approvals, Conference Highlights ASCO

Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

FDA Approvals, Multiple Myeloma, Conference Highlights ASCO

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

FDA Approvals, Conference Highlights ASCO

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

FDA Approvals, Conference Highlights ASCO

Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma

FDA Approvals, Urothelial Cancer, Conference Highlights ASCO

Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer

FDA Approvals, Select Drug Profiles

Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer

FDA Approvals, Select Drug Profiles

Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer

7
8
9
10
11
12
13

Page 10 of 31
Results 91 - 100 of 305